RejuvionBio

Rejuvion is a Swiss biotechnology company and ETH Zurich spin-off dedicated to developing therapies that rejuvenate the extracellular matrix (ECM) to treat age-related diseases. The company's core technology is a proprietary screening platform that identifies small molecules and other agents capable of restoring the health and elasticity of the ECM, which is a critical component of tissue longevity. By targeting the structural environment of cells rather than just the cells themselves, Rejuvion aims to address a broad range of conditions, including skin aging and various forms of fibrosis. Currently in the pre-clinical stage, the company is focused on advancing its lead candidates and expanding its platform's capabilities in the field of regenerative medicine.